INDICATIONS AND USAGE（适应症）

VOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have:

genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor.

genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.

Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.

DOSAGE（服用剂量）

The recommended dosage of VOSEVI is one tablet, taken orally, once daily with food. One tablet of VOSEVI contains 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir. Table 1 shows the recommended treatment regimen and duration based on patient population.

ADVERSE REACTIONS（不良反应）

Serious Symptomatic Bradycardia When Coadministered with Amiodarone

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/17ffc094-8ca7-45d2-80d8-fd043bc9a221/spl-doc?hl=velpatasvir

Voseviinformation